Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis

Journal of Dermatological Science

Volumn 53, Issue 1, 2009, Pages 34-39

  Shibata, Sayaka ^a   Tada, Yayoi ^a   Komine, Mayumi ^a   Hattori, Naoko ^b   Osame, Satsuki ^c   Kanda, Naoko ^c   Watanabe, Shinichi ^c   Saeki, Hidehisa ^a   Tamaki, Kunihiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Toshiba Hospital   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti cyclic citrullinated peptide antibodies; Interleukin 23p19; Psoriatic arthritis

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; INTERLEUKIN 12P40; INTERLEUKIN 23P19; METHOTREXATE; RHEUMATOID FACTOR; STROMELYSIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SEROPREVALENCE;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-23 SUBUNIT P19; JAPAN; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR;

EID: 57549092371     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2008.06.008     Document Type: Article

References (42)

1. Shbeeb M., Uramoto K.M., Gibson L.E., O'Fallon W.M., and Gabriel S.E. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 27 (2000) 1247-1250
2. Gisondi P., Girolomoni G., Sampogna F., Tabolli S., and Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 15 (2005) 279-283
3. Gelfand J.M., Gladman D.D., Mease P.J., Smith N., Margolis D.J., Nijsten T., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53 (2005) 573
4. Moll J.M., and Wright V. Psoriatic arthritis. Semin Arthritis Rheum 3 (1973) 55-78
5. Bogliolo L., Alpini C., Caporali R., Scire C.A., Moratti R., and Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 32 (2005) 511-515
6. Vander Cruyssen B., Hoffman I.E., Zmierczak H., Van den Berghe M., Kruithof E., De Rycke L., et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64 (2005) 1145-1149
7. Inanc N., Dalkilic E., Kamali S., Kasapoglu-Gunal E., Elbir Y., Direskeneli H., et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26 (2007) 17-23
8. Schellekens G.A., Visser H., de Jong B.A., van den Hoogen F.H., Hazes J.M., Breedveld F.C., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43 (2000) 155-163
9. Avouac J., Gossec L., and Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65 (2006) 845-851
10. Nienhuis R.L., and Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 23 (1964) 302-305
11. Young B.J., Mallya R.K., Leslie R.D., Clark C.J., and Hamblin T.J. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 2 (1979) 97-99
12. Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., and van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101 (1998) 273-281
13. van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., de Jong B.A., Breedveld F.C., Verweij C.L., et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50 (2004) 709-715
14. Candia L., Marquez J., Gonzalez C., Santos A.M., Londono J., Valle R., et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol 12 (2006) 226-229
15. Korendowych E., Owen P., Ravindran J., Carmichael C., and McHugh N. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 44 (2005) 1056-1060
16. Toichi E., Torres G., McCormick T.S., Chang T., Mascelli M.A., Kauffman C.L., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 177 (2006) 4917-4926
17. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., and Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278 (2003) 1910-1914
18. Nickoloff B.J. Cracking the cytokine code in psoriasis. Nat Med 13 (2007) 242-244
19. Tada Y., Asahina A., Takekoshi T., Kishimoto E., Mitsui H., Saeki H., et al. Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A. Br J Dermatol 154 (2006) 1180-1183
20. Brennan F., and Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 19 (2007) 296-301
21. Gladman D.D., Shuckett R., Russell M.L., Thorne J.C., and Schachter R.K. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med 62 (1987) 127-141
22. Gladman D.D. Current concepts in psoriatic arthritis. Curr Opin Rheumatol 14 (2002) 361-366
23. Ribbens C., Martin y Porras M., Franchimont N., Kaiser M.J., Jaspar J.M., Damas P., et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61 (2002) 161-166
24. Oldberg A., Antonsson P., Lindblom K., and Heinegard D. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem 267 (1992) 22346-22350
25. Hedbom E., Antonsson P., Hjerpe A., et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 267 (1992) 6132-6136
26. Saxne T., and Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31 (1992) 583-591
27. Neidhart M., Hauser N., Paulsson M., DiCesare P.E., Michel B.A., and Hauselmann H.J. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 36 (1997) 1151-1160
28. Miossec P., Naviliat M., Dupuy d'Angeac A., Sany J., and Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum 33 (1990) 1180-1187
29. Feldmann M., Brennan F.M., and Maini R. Cytokines in autoimmune disorders. Int Rev Immunol 17 (1998) 217-228
30. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
31. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337 (1997) 141-147
32. den Broeder A., van de Putte L., Rau R., Schattenkirchner M., Van Riel P., Sander O., et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29 (2002) 2288-2298
33. Ravindran V., Scott D.L., and Choy E.H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biologic agents for psoriatic arthritis. Ann Rheum Dis (2007)
34. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
35. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
36. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
37. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199 (2004) 125-130
38. Piskin G., Sylva-Steenland R.M., Bos J.D., and Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176 (2006) 1908-1915
39. Yawalkar N., Karlen S., Hunger R., Brand C.U., and Braathen L.R. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 111 (1998) 1053-1057
40. Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
41. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123 (2004) 1037-1044
42. Kim H.R., Kim H.S., Park M.K., Cho M.L., Lee S.H., and Kim H.Y. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol 36 (2007) 259-264